Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
In a publication from 2007, investigators from Arrow Pharmaceuticals told us that A-60444 (later renamed to RSV-604) was already in Phase 2. Since then, it has been very quiet about this compound. Some have suggested that Novartis has stopped development [1], an impression supported by the fact that the drug is Continue reading Following The Publication Trail of Two RSV Drugs
Why are there so few boron-containing drugs on the market? The cancer drug bortezumib (Velcade®) may be the only better-known drug on the market with a boron atom in its structure.[1] Among antibiotics, there is Kerydin™ (tavaborole), an approved topical solution for the treatment of onychomycosis caused by Trichophyton but Continue reading Not So Boring: Boron-Containing Antibiotics Create a Stir
Several reasons have been proposed as explanations why so many S. aureus vaccines have failed in clinical trials. Clearly, the organism has a battery of virulence factors which may require a multipronged approach and neutralizing just a single mechanism with a specific mAb may not suffice.